SLC5A2 and heart failure: A synthesized summary of available retrospective studies and one prospective study indicates that the use of SGLT2 inhibitors in oncology patients, particularly those with type 2 diabetes, is associated with a significant reduction in all-cause mortality and heart failure hospitalizations.